Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Perspective: Neuroregenerative Nutrition.

Steindler DA, Reynolds BA.

Adv Nutr. 2017 Jul 14;8(4):546-557. doi: 10.3945/an.117.015388. Print 2017 Jul.

PMID:
28710142
2.

Efficacy and Blood Plasmalogen Changes by Oral Administration of Plasmalogen in Patients with Mild Alzheimer's Disease and Mild Cognitive Impairment: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.

Fujino T, Yamada T, Asada T, Tsuboi Y, Wakana C, Mawatari S, Kono S.

EBioMedicine. 2017 Mar;17:199-205. doi: 10.1016/j.ebiom.2017.02.012. Epub 2017 Feb 24.

3.

The Effects of Long-Term Saturated Fat Enriched Diets on the Brain Lipidome.

Giles C, Takechi R, Mellett NA, Meikle PJ, Dhaliwal S, Mamo JC.

PLoS One. 2016 Dec 1;11(12):e0166964. doi: 10.1371/journal.pone.0166964. eCollection 2016.

4.

Molecular cloning, heterologous expression, and enzymatic characterization of lysoplasmalogen-specific phospholipase D from Thermocrispum sp.

Matsumoto Y, Kashiwabara N, Oyama T, Murayama K, Matsumoto H, Sakasegawa SI, Sugimori D.

FEBS Open Bio. 2016 Oct 17;6(11):1113-1130. eCollection 2016 Nov. Erratum in: FEBS Open Bio. 2016 Dec 20;7(1):118.

5.

Vitamin E, Turmeric and Saffron in Treatment of Alzheimer's Disease.

Adalier N, Parker H.

Antioxidants (Basel). 2016 Oct 25;5(4). pii: E40. Review.

6.

Measurement of Ether Phospholipids in Human Plasma with HPLC-ELSD and LC/ESI-MS After Hydrolysis of Plasma with Phospholipase A1.

Mawatari S, Hazeyama S, Fujino T.

Lipids. 2016 Aug;51(8):997-1006. doi: 10.1007/s11745-016-4170-9. Epub 2016 Jul 7.

7.

Targeted lipidomics distinguishes patient subgroups in mild cognitive impairment (MCI) and late onset Alzheimer's disease (LOAD).

Wood PL, Locke VA, Herling P, Passaro A, Vigna GB, Volpato S, Valacchi G, Cervellati C, Zuliani G.

BBA Clin. 2015 Nov 14;5:25-8. doi: 10.1016/j.bbacli.2015.11.004. eCollection 2016 Jun.

8.

Neuronal Orphan G-Protein Coupled Receptor Proteins Mediate Plasmalogens-Induced Activation of ERK and Akt Signaling.

Hossain MS, Mineno K, Katafuchi T.

PLoS One. 2016 Mar 2;11(3):e0150846. doi: 10.1371/journal.pone.0150846. eCollection 2016.

9.

Peroxisomes in brain development and function.

Berger J, Dorninger F, Forss-Petter S, Kunze M.

Biochim Biophys Acta. 2016 May;1863(5):934-55. doi: 10.1016/j.bbamcr.2015.12.005. Epub 2015 Dec 11. Review.

10.

Changes in Plasma Lipids during Exposure to Total Sleep Deprivation.

Chua EC, Shui G, Cazenave-Gassiot A, Wenk MR, Gooley JJ.

Sleep. 2015 Nov 1;38(11):1683-91. doi: 10.5665/sleep.5142.

11.

Age-dependent biochemical dysfunction in skeletal muscle of triple-transgenic mouse model of Alzheimer`s disease.

Monteiro-Cardoso VF, Castro M, Oliveira MM, Moreira PI, Peixoto F, Videira RA.

Curr Alzheimer Res. 2015;12(2):100-15.

12.

Metabolomic Identification in Cerebrospinal Fluid of the Effects of High Dietary Cholesterol in a Rabbit Model of Alzheimer's Disease.

Liu QY, Bingham EJ, Twine SM, Geiger JD, Ghribi O.

Metabolomics (Los Angel). 2012 Mar 29;2(3):109.

13.

PPAR- γ impairment alters peroxisome functionality in primary astrocyte cell cultures.

Di Cesare Mannelli L, Zanardelli M, Micheli L, Ghelardini C.

Biomed Res Int. 2014;2014:546453. doi: 10.1155/2014/546453. Epub 2014 Mar 4.

14.

Plasmalogens rescue neuronal cell death through an activation of AKT and ERK survival signaling.

Hossain MS, Ifuku M, Take S, Kawamura J, Miake K, Katafuchi T.

PLoS One. 2013 Dec 20;8(12):e83508. doi: 10.1371/journal.pone.0083508. eCollection 2013.

15.

Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology.

Wood PL.

Neuropsychopharmacology. 2014 Jan;39(1):24-33. doi: 10.1038/npp.2013.167. Epub 2013 Jul 11. Review.

16.

Changes in phospholipid composition of erythrocyte membrane in Alzheimer's disease.

Oma S, Mawatari S, Saito K, Wakana C, Tsuboi Y, Yamada T, Fujino T.

Dement Geriatr Cogn Dis Extra. 2012 Jan;2(1):298-303. doi: 10.1159/000341603. Epub 2012 Aug 15.

17.

Anti-inflammatory/anti-amyloidogenic effects of plasmalogens in lipopolysaccharide-induced neuroinflammation in adult mice.

Ifuku M, Katafuchi T, Mawatari S, Noda M, Miake K, Sugiyama M, Fujino T.

J Neuroinflammation. 2012 Aug 13;9:197.

18.

Plasmalogens inhibit APP processing by directly affecting γ-secretase activity in Alzheimer's disease.

Rothhaar TL, Grösgen S, Haupenthal VJ, Burg VK, Hundsdörfer B, Mett J, Riemenschneider M, Grimm HS, Hartmann T, Grimm MO.

ScientificWorldJournal. 2012;2012:141240. doi: 10.1100/2012/141240. Epub 2012 Apr 1.

19.

Lipidomics of Alzheimer's disease: current status.

Wood PL.

Alzheimers Res Ther. 2012 Feb 1;4(1):5. doi: 10.1186/alzrt103.

20.

Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease.

Wood PL, Smith T, Lane N, Khan MA, Ehrmantraut G, Goodenowe DB.

Lipids Health Dis. 2011 Dec 5;10:227. doi: 10.1186/1476-511X-10-227.

Supplemental Content

Support Center